and remember the blue sky for relenza alone all those yrs ago when first listed was $9 in yester-year dollars - Today equivalent - say $18 - and relenza was'nt negotiated in the midst of a pandemic - nor was it presented to gsk on a plate after stage 3 trials success - so imo we have heaps of blue sky potential - which will probably be realised once another couple quarters royalties come thru - providing some reality for the insto's and os investors - add to that total tamiflu resistance and we will be looking past the blue sky into the stratisphere.
Add to My Watchlist
What is My Watchlist?